Close

Pre-Open Movers: Karuna Surges on Study Data, Bed Bath & Beyond Climbs

August 8, 2022 8:52 AM EDT

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Magic Empire Global Limited (NASDAQ: MEGL) +100%; recent IPO extends gain aftering surging in debut.

Karuna Therapeutics Inc. (NASDAQ: KRTX) +53%; today announced positive topline results from its Phase 3 EMERGENT-2 trial evaluating the efficacy, safety, and tolerability of its lead investigational therapy, KarXT (xanomeline-trospium), in adults with schizophrenia. The trial met its primary endpoint, with KarXT demonstrating a statistically significant and clinically meaningful 9.6-point reduction in the Positive and Negative Syndrome Scale (PANSS) total score compared to placebo (-21.2 KarXT vs. -11.6 placebo, p<0.0001) at Week 5 (Cohen’s d effect size of 0.61). KarXT also demonstrated an early and sustained statistically significant reduction of symptoms, as assessed by PANSS total score, starting at Week 2 and maintained such reduction through all timepoints in the trial.

Bed Bath & Beyond (NASDAQ: BBBY) +40% on continued momentum in meme stocks,

  • AMC Entertainment (NYSE: AMC) also higher, +7%.

Cyberoptics Corp (NASDAQ: CYBE) +30%; Nordson Corporation (Nasdaq: NDSN) has signed a definitive agreement for the acquisition of CyberOptics Corporation (Nasdaq: CYBE), a leading global developer and manufacturer of high-precision 3D optical sensing technology solutions.The all-cash transaction is valued at $54.00 a share, or approximately $380 million net of cash acquired, reflecting a valuation of 18.5 times CyberOptics trailing twelve months EBITDA, and 14.5 times net of cost synergies.

Kodiak Sciences Inc. (NASDAQ: KOD) +30%; today announced that its BEACON Phase 3 study of tarcocimab tedromer (KSI-301; tarcocimab), its novel antibody biopolymer conjugate, met the primary endpoint of non-inferior change from baseline in visual acuity at week 24 compared to aflibercept in patients with macular edema due to retinal vein occlusion. Tarcocimab also demonstrated robust anatomic responses and a favorable safety profile. After two initial monthly loading doses, tarcocimab was dosed every two months compared to consistent monthly dosing for aflibercept.

Signify Health, Inc. (NYSE: SGFY) +20%; CVS is planning to bid for Signify Health (NASDAQ: SGFY), according to a report in the Dow Jones.

Coinbase (NASDAQ: COIN) +9%; related names climb as Bitcoin tops $24,000.

  • Microstrategy, Inc. (NASDAQ: MSTR) +6.5%
  • Riot Blockchain (NASDAQ: RIOT) +7%
  • Marathon Digital Holdings (NASDAQ: MARA) +8%

First Solar (NASDAQ: FSLR) +6%, Upgraded at JPMorgan and Guggenheim.

Palantir (NYSE: PLTR) -15%; Guidance misses consensus.

Roku (NASDAQ: ROKU) -2%; cut to sell at Pivotal Research.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Special Reports

Related Entities

JPMorgan, Definitive Agreement, IPO, Bitcoin, Pre Market Movers, Guggenheim